Your browser is no longer supported. Please, upgrade your browser.
Settings
XOMA XOMA Corporation daily Stock Chart
XOMA [NASD]
XOMA Corporation
Index- P/E- EPS (ttm)-7.13 Insider Own0.30% Shs Outstand7.33M Perf Week12.13%
Market Cap147.70M Forward P/E- EPS next Y-1.32 Insider Trans-68.24% Shs Float6.72M Perf Month167.24%
Income-46.00M PEG- EPS next Q-0.81 Inst Own37.40% Short Float9.81% Perf Quarter201.65%
Sales12.30M P/S12.01 EPS this Y-154.10% Inst Trans5.71% Short Ratio4.04 Perf Half Y233.33%
Book/sh-3.84 P/B- EPS next Y54.90% ROA-206.50% Target Price17.00 Perf Year97.55%
Cash/sh- P/C- EPS next 5Y19.00% ROE148.90% 52W Range3.96 - 20.40 Perf YTD377.49%
Dividend- P/FCF- EPS past 5Y15.60% ROI- 52W High-1.23% Beta3.05
Dividend %- Quick Ratio1.10 Sales past 5Y-37.50% Gross Margin- 52W Low408.84% ATR1.41
Employees18 Current Ratio1.10 Sales Q/Q2358.20% Oper. Margin- RSI (14)81.91 Volatility7.03% 11.55%
OptionableNo Debt/Eq- EPS Q/Q100.90% Profit Margin- Rel Volume1.84 Prev Close18.99
ShortableYes LT Debt/Eq- EarningsAug 09 Payout- Avg Volume162.86K Price20.15
Recom2.00 SMA2038.58% SMA5097.43% SMA200189.64% Volume292,608 Change6.11%
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jan-06-11Reiterated Ladenburg Thalmann Buy $12 → $16
Jan-04-11Reiterated Wedbush Outperform $12 → $16
Sep-19-17 07:00AM  XOMA to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-11-17 07:00AM  XOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics GlobeNewswire
Sep-07-17 02:17PM  ETFs with exposure to XOMA Corp. : September 7, 2017 Capital Cube +12.60%
Sep-06-17 08:10AM  Today's Research Reports on Stocks to Watch: Insmed Inc. and XOMA Corporation ACCESSWIRE
07:20AM  [$$] Novartis Deal Could Send Xoma Stock to $19 Barrons.com
07:00AM  XOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-28-17 08:20AM  Today's Research Reports on Stocks to Watch: Adamas Pharmaceuticals and XOMA Corporation ACCESSWIRE
Aug-25-17 05:56PM  ETFs with exposure to XOMA Corp. : August 25, 2017 Capital Cube +24.30%
07:00AM  XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio GlobeNewswire
Aug-16-17 10:01AM  XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-09-17 04:30PM  XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-17 04:30PM  XOMA Reports Second Quarter 2017 Financial Results GlobeNewswire
May-18-17 07:00AM  XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development GlobeNewswire
May-15-17 04:05PM  XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference GlobeNewswire
May-09-17 06:32PM  Xoma reports 1Q loss Associated Press
04:05PM  XOMA Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-25-17 07:30AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and XOMA Accesswire
Apr-24-17 07:00AM  XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition GlobeNewswire -8.02%
Apr-21-17 05:42AM  XOMA (XOMA) Shares March Higher, Can It Continue? Zacks
Apr-18-17 07:00AM  XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program GlobeNewswire +14.00%
Mar-28-17 07:00AM  XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-27-17 05:02PM  XOMA CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfe +5.62%
Mar-23-17 09:30AM  Idera Pharmaceuticals and XOMA Find Paths to Financial Growth Accesswire +8.19%
07:00AM  XOMA Announces Four Presentations at the 2017 ENDO Meeting GlobeNewswire
Mar-22-17 01:04PM  XOMA CORP Financials +12.99%
07:17AM  XOMA CORP Files SEC form 8-K, Other Events
07:00AM  XOMA Announces Full Repayment of Hercules Technology Growth Capital Debt Obligation GlobeNewswire
Mar-17-17 12:54PM  Xoma Stock Tumbles 3.81% After Earnings Release GuruFocus.com
Mar-16-17 07:28AM  Xoma reports 4Q loss Associated Press
07:16AM  XOMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q4 2016 XOMA Corp Earnings Release - Before Market Open
07:00AM  XOMA Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-14-17 07:00AM  XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017 GlobeNewswire
Mar-08-17 04:32PM  XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers +6.36%
Mar-06-17 08:02AM  XOMA CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-28-17 07:00AM  XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-16-17 05:12PM  XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Security -7.37%
07:00AM  XOMA Appoints Matthew Perry to its Board of Directors GlobeNewswire
Feb-15-17 09:30AM  Biotech Industry Poised for a Breakout in 2017? Today's Reports on Cellect Biotechnology and XOMA Accesswire
Feb-13-17 11:00AM  Xoma Launches $25 Million Registered Offering Investopedia +19.60%
11:00AM  Xoma Launches $25 Million Registered Offering at Investopedia
07:01AM  XOMA CORP Files SEC form 8-K, Other Events
07:00AM  XOMA Announces Pricing of $25 Million Registered Offering of Common Stock and Convertible Preferred Stock GlobeNewswire
Feb-01-17 03:12PM  XOMA Says Its Drug Candidate 358 Is Progressing at Investopedia +9.56%
Jan-31-17 04:00PM  XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery GlobeNewswire
Jan-17-17 04:46PM  XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Jan-03-17 02:22PM  13 Emerging Biotechs With Catalysts In 2017 +17.77%
Dec-22-16 06:04AM  XOMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of
Dec-21-16 05:00PM  XOMA Announces up to $22 Million Generated from Sale of Royalty Streams from Two License Agreements to HealthCare Royalty Partners and Provides Corporate Update GlobeNewswire
Dec-16-16 12:29PM  ETFs with exposure to XOMA Corp. : December 16, 2016
Dec-12-16 11:21PM  How XOMA Corp (XOMA) Stacks Up Against Its Peers at Insider Monkey
Dec-05-16 12:51PM  ETFs with exposure to XOMA Corp. : December 5, 2016
Nov-16-16 01:34PM  ETFs with exposure to XOMA Corp. : November 16, 2016
Nov-15-16 10:39AM  XOMA Challenged With A 'Major Financing Overhang' +8.59%
Nov-14-16 11:51AM  XOMA Corp. :XOMA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016
07:20AM  XOMA downgraded by Wedbush
06:19AM  XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers
Nov-09-16 09:13AM  Xoma reports 3Q loss
09:03AM  XOMA CORP Files SEC form 10-Q, Quarterly Report
09:00AM  XOMA Reports Third Quarter 2016 Achievements and Financial Results GlobeNewswire
Nov-08-16 09:00AM  New XOMA Antibodies Unveiled at The Society for Immunotherapy of Cancer 31st Annual Meeting GlobeNewswire
Nov-02-16 02:46PM  XOMA CORP Files SEC form 8-K, Other Events
Oct-23-16 04:23PM  5 Biotech Penny Stocks Smart Money Is Piling On at Insider Monkey
Oct-20-16 01:57PM  Xoma Phase 2 Pediatric Trial Wins UK Nod (XOMA) at Investopedia
Oct-19-16 09:00AM  XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism GlobeNewswire -14.90%
Oct-18-16 11:22AM  ETFs with exposure to XOMA Corp. : October 18, 2016 -11.31%
07:03AM  Splits Calendar: XOMA splits before market open today (1:20 ratio)
06:02AM  XOMA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters
Oct-17-16 10:22AM  Xoma Sets 1-for-20 Reverse Stock Split (XOMA) at Investopedia -9.79%
Oct-14-16 04:09PM  XOMA Announces Reverse Stock Split GlobeNewswire -6.72%
Sep-30-16 10:14AM  ETFs with exposure to XOMA Corp. : September 30, 2016
Sep-19-16 04:02PM  XOMA CORP Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans -5.30%
Sep-16-16 05:14PM  XOMA Reports Success in Insulin Trials (XOMA) at Investopedia -15.13%
Sep-15-16 07:26PM  XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies GlobeNewswire
Sep-09-16 11:35AM  ETFs with exposure to XOMA Corp. : September 9, 2016
Sep-06-16 09:00AM  XOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016 GlobeNewswire +7.20%
Sep-02-16 04:22PM  XOMA CORP Files SEC form 8-K, Other Events
Aug-11-16 02:33PM  XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference GlobeNewswire
01:20PM  ETFs with exposure to XOMA Corp. : August 11, 2016
Aug-09-16 12:14PM  XOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
Aug-03-16 05:37PM  Xoma reports 2Q loss
04:17PM  XOMA CORP Files SEC form 10-Q, Quarterly Report
04:01PM  XOMA Reports Second Quarter 2016 Achievements and Financial Results GlobeNewswire
Jul-20-16 09:00AM  XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism GlobeNewswire +14.93%
Jul-05-16 02:06PM  XOMA to Present at the Cantor Fitzgerald Healthcare Conference GlobeNewswire
Jun-28-16 09:01AM  XOMA Initiates Phase 2 Proof-of-Concept Study of XOMA 213 GlobeNewswire
Jun-20-16 03:29PM  ETFs with exposure to XOMA Corp. : June 20, 2016
Jun-03-16 09:08AM  Biotech Industrys Stocks Get Research Review
Jun-02-16 01:48PM  XOMA to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-23-16 06:02AM  XOMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security
May-19-16 08:09PM  ETFs with exposure to XOMA Corp. : May 20, 2016
May-18-16 02:01PM  XOMA Corp. :XOMA-US: Earnings Analysis: Q1, 2016 By the Numbers
May-04-16 05:47PM  Xoma reports 1Q loss
04:09PM  XOMA CORP Files SEC form 10-Q, Quarterly Report
04:01PM  XOMA Reports First Quarter 2016 Operational Achievements and Financial Results GlobeNewswire
Apr-27-16 09:00AM  XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery GlobeNewswire
Apr-19-16 11:06AM  Can The Uptrend Continue for XOMA Corp (XOMA)?
Apr-07-16 09:14AM  4 Growth Stocks to Buy Near Their 52-Week Lows
Apr-04-16 09:00AM  XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting GlobeNewswire +5.31%
Mar-29-16 11:06AM  ETFs with exposure to XOMA Corp. : March 29, 2016
XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Varian JohnDirectorMay 16Sale6.2439,540246,9192,344May 18 03:02 PM
Neal James RVP Business DevelopmentMar 21Sale5.405,10527,56915,366Mar 23 10:45 AM
BURNS THOMAS M.VP, Finance & Chief FinancialMar 21Sale5.402,59814,0306,555Mar 23 10:31 AM
Neal James RVP Business DevelopmentFeb 01Sale4.5219588120,471Feb 01 04:47 PM
Neal James RVP Business DevelopmentJan 09Sale5.1512564420,666Jan 10 12:21 PM
Varian JohnDirectorDec 21Sale5.7513,54977,90741,884Dec 23 06:38 PM
SCANNON PATRICK J MD PHDExec. VP & CSODec 21Sale5.753,23018,5738,217Dec 23 06:36 PM
Neal James RVP Business DevelopmentNov 01Sale5.2515078820,541Nov 03 07:38 PM
Neal James RVP Business DevelopmentOct 07Sale0.452,5001,120413,839Oct 11 05:26 PM